Cadila Healthcare Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news appearing in Economic Times on January 18, 2017 titled "Cadila Set to Buy US Firm for $171 m."Cadila Healthcare Ltd response is enclosed. Zydus receives final approval from the USFDA for Methotrexate Tablets USP
Cadila Healthcare Ltd has submitted to BSE a copy of Press Release dated January 18, 2017 titled ''Zydus receives final approval from the USFDA for Methotrexate Tablets USP". Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing in Economic Times on January 18, 2017 titled "Cadila Set to Buy US Firm for $171 m."The reply is awaited. Zydus announces settlement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. on Livalo (pitavastatin calcium) tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated January 17, 2017, titled "Zydus announces settlement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. on Livalo (pitavastatin calcium) tablets". Cadila settles patent litigation related to anti-seizure drug
Pharmaceutical major Cadila Healthcare Ltd and its subsidiary Zydus Pharmaceuticals (USA) Inc., on Friday, announced that they have finalised an agreement with Upsher-Smith Laboratories, Inc. to... Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy XR (topiramate) extended-release capsules
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated January 13, 2017, titled "Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy XR (topiramate) extended-release capsules". Shareholding for the Period Ended December 31, 2016
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Updates
Cadila Healthcare Ltd has informed BSE that the Company is going to participate in JP Morgan Investor Conference scheduled to be held on January 09, 2017 to January 12, 2017 in US.